Literature DB >> 30630041

A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition.

Joseph H Neale1, Rafal Olszewski2.   

Abstract

The peptide transmitter N-acetylaspartylglutamate (NAAG) and its receptor, the type 3 metabotropic glutamate receptor (mGluR3, GRM3), are prevalent and widely distributed in the mammalian nervous system. Drugs that inhibit the inactivation of synaptically released NAAG have procognitive activity in object recognition and other behavioral models. These inhibitors also reverse cognitive deficits in animal models of clinical disorders. Antagonists of mGluR3 block these actions and mice that are null mutant for this receptor are insensitive to the actions of these procognitive drugs. A positive allosteric modulator of this receptor also has procognitive activity. While some data suggest that drugs acting on mGluR3 achieve their procognitive action by increasing arousal during acquisition training, exploration of the procognitive efficacy of NAAG is in its early stages and thus substantial opportunities exist to define the breadth and nature of this activity.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glutamate carboxypeptidase II; Memory; Metabotropic receptors; N-acetylaspartylglutamate; NAAG; mGluR3

Mesh:

Substances:

Year:  2019        PMID: 30630041      PMCID: PMC6397785          DOI: 10.1016/j.nlm.2019.01.006

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  49 in total

1.  Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury.

Authors:  Yang Gao; Siyi Xu; Zhenwen Cui; Mingkun Zhang; Yingying Lin; Lei Cai; Zhugang Wang; Xingguang Luo; Yan Zheng; Yong Wang; Qizhong Luo; Jiyao Jiang; Joseph H Neale; Chunlong Zhong
Journal:  J Neurochem       Date:  2015-04-28       Impact factor: 5.372

Review 2.  Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert.

Authors:  Andreas Reiner; Joshua Levitz
Journal:  Neuron       Date:  2018-06-27       Impact factor: 17.173

3.  NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats.

Authors:  Chunlong Zhong; Xueren Zhao; Jayaprakash Sarva; Alan Kozikowski; Joseph H Neale; Bruce G Lyeth
Journal:  J Neurotrauma       Date:  2005-02       Impact factor: 5.269

Review 4.  Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family.

Authors:  Joseph H Neale; Rafal T Olszewski; Daiying Zuo; Karolina J Janczura; Caterina P Profaci; Kaleen M Lavin; John C Madore; Tomasz Bzdega
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

Review 5.  The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia.

Authors:  Joseph H Neale; Rafal T Olszewski; Laura M Gehl; Barbara Wroblewska; Tomasz Bzdega
Journal:  Trends Pharmacol Sci       Date:  2005-09       Impact factor: 14.819

6.  The metabotropic glutamate receptor mGluR3 is critically required for hippocampal long-term depression and modulates long-term potentiation in the dentate gyrus of freely moving rats.

Authors:  Beatrice Pöschel; Barbara Wroblewska; Uwe Heinemann; Denise Manahan-Vaughan
Journal:  Cereb Cortex       Date:  2005-01-05       Impact factor: 5.357

7.  Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys.

Authors:  Simona Spinelli; Theresa Ballard; Silvia Gatti-McArthur; Grayson J Richards; Martin Kapps; Thomas Woltering; Jurgen Wichmann; Heinz Stadler; Joram Feldon; Christopher R Pryce
Journal:  Psychopharmacology (Berl)       Date:  2005-01-28       Impact factor: 4.530

8.  The role of group II metabotropic glutamate receptors in cognition and anxiety: comparative studies in GRM2(-/-), GRM3(-/-) and GRM2/3(-/-) knockout mice.

Authors:  Bianca De Filippis; Louisa Lyon; Amy Taylor; Tracy Lane; Philip W J Burnet; Paul J Harrison; David M Bannerman
Journal:  Neuropharmacology       Date:  2014-08-23       Impact factor: 5.250

9.  A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA.

Authors:  Takahiro Nonaka; Toshihiko Yamada; Tatsuhiro Ishimura; Daiying Zuo; John R Moffett; Joseph H Neale; Tatsuo Yamamoto
Journal:  Mol Pain       Date:  2017-01       Impact factor: 3.395

10.  NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.

Authors:  Rafal T Olszewski; Karolina J Janczura; Tomasz Bzdega; Elise K Der; Faustino Venzor; Brennen O'Rourke; Timothy J Hark; Kirsten E Craddock; Shankar Balasubramanian; Charbel Moussa; Joseph H Neale
Journal:  Neurochem Res       Date:  2017-03-11       Impact factor: 3.996

View more
  11 in total

1.  Inhibition of glutamate-carboxypeptidase-II in dorsolateral prefrontal cortex: potential therapeutic target for neuroinflammatory cognitive disorders.

Authors:  Shengtao Yang; Dibyadeep Datta; Alvaro Duque; Yury M Morozov; Jon Arellano; Barbara S Slusher; Min Wang; Amy F T Arnsten
Journal:  Mol Psychiatry       Date:  2022-06-22       Impact factor: 13.437

Review 2.  Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.

Authors:  Shalini Dogra; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2022-03-03       Impact factor: 4.054

3.  Evidence of NAAG-family tripeptide NAAG2 in the Drosophila nervous system.

Authors:  Emily M Kozik; Elaine M Marzluff; Clark A Lindgren
Journal:  J Neurochem       Date:  2020-09-21       Impact factor: 5.546

4.  N-Acetylaspartyl-Glutamate Metabolism in the Cingulated Cortices as a Biomarker of the Etiology in ASD: A 1H-MRS Model.

Authors:  Carmen Jiménez-Espinoza; Francisco Marcano Serrano; José Luis González-Mora
Journal:  Molecules       Date:  2021-01-28       Impact factor: 4.411

5.  Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology.

Authors:  David J Braun; David K Powell; Christopher J McLouth; Saktimayee M Roy; D Martin Watterson; Linda J Van Eldik
Journal:  PLoS One       Date:  2022-01-26       Impact factor: 3.752

6.  Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis.

Authors:  Kristen R Hollinger; Anjali Sharma; Carolyn Tallon; Lyndah Lovell; Ajit G Thomas; Xiaolei Zhu; Robyn Wiseman; Ying Wu; Siva P Kambhampati; Kevin Liaw; Rishi Sharma; Camilo Rojas; Rana Rais; Sujatha Kannan; Rangaramanujam M Kannan; Barbara S Slusher
Journal:  Nanotheranostics       Date:  2022-01-01

7.  Glutamate Carboxypeptidase II in Aging Rat Prefrontal Cortex Impairs Working Memory Performance.

Authors:  Dibyadeep Datta; Shannon N Leslie; Elizabeth Woo; Nishita Amancharla; Ayah Elmansy; Miguel Lepe; Adam P Mecca; Barbara S Slusher; Angus C Nairn; Amy F T Arnsten
Journal:  Front Aging Neurosci       Date:  2021-11-15       Impact factor: 5.750

Review 8.  N-Acetyl-Aspartyl-Glutamate in Brain Health and Disease.

Authors:  Cecilie Morland; Kaja Nordengen
Journal:  Int J Mol Sci       Date:  2022-01-23       Impact factor: 5.923

9.  Human Gray and White Matter Metabolomics to Differentiate APOE and Stage Dependent Changes in Alzheimer's Disease.

Authors:  Tyler C Hammond; Xin Xing; Lucy M Yanckello; Arnold Stromberg; Ya-Hsuan Chang; Peter T Nelson; Ai-Ling Lin
Journal:  J Cell Immunol       Date:  2021

10.  Glutamate Metabotropic Receptor Type 3 (mGlu3) Localization in the Rat Prelimbic Medial Prefrontal Cortex.

Authors:  Elizabeth Woo; Dibyadeep Datta; Amy F T Arnsten
Journal:  Front Neuroanat       Date:  2022-04-04       Impact factor: 3.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.